Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
INTERLEUKIN GENETICS INC (ILIU)
|
Add to portfolio |
|
|
|
| Price: |
$0.00
| | Metrics |
| OS: |
229.5
|
M
| |
|
|
| Market cap: |
$1.03
|
M
| |
|
|
|
Net debt:
|
$2.34
|
M
| |
|
|
|
EV:
|
$3.38
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($7.1)
|
M
| |
|
|
|
EBIT
|
($7.6)
|
M
| |
|
|
| EPS |
($0.04)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
| Revenues | 2.5 | 1.4 | 1.8 | 2.4 | 2.2 | 2.9 | 2.0 | 1.1 |
| Revenue growth | 74.4% | -20.4% | -25.5% | 8.6% | -21.7% | 43.1% | 85.2% | |
| Cost of goods sold | 1.6 | 1.4 | 1.4 | 1.6 | 1.3 | 1.5 | 1.6 | 1.2 |
| Gross profit | 0.9 | 0.0 | 0.4 | 0.8 | 0.9 | 1.3 | 0.4 | -0.1 |
| Gross margin | 36.3% | 1.9% | 20.7% | 32.8% | 40.6% | 46.5% | 18.9% | -11.6% |
| Selling, general and administrative | 6.1 | 5.9 | 5.8 | 6.6 | 4.2 | 4.7 | 5.5 | 5.6 |
| Research and development | 1.5 | 1.3 | 0.8 | 0.7 | 1.3 | 1.4 | 1.4 | 3.2 |
| EBITA | -6.5 | -7.2 | -6.2 | -6.5 | -4.6 | -4.7 | -6.1 | -8.9 |
| EBITA margin | -258.7% | -496.3% | -344.4% | -266.8% | -203.7% | -164.9% | -304.8% | -826.6% |
| Amortization of intangibles | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| EBIT | -6.7 | -7.3 | -6.3 | -6.6 | -4.7 | -4.8 | -6.2 | -9.0 |
| EBIT margin | -265.5% | -505.8% | -349.6% | -271.3% | -208.8% | -169.0% | -310.6% | -837.3% |
| Pre-tax income | -7.4 | -7.9 | -6.3 | -7.1 | -5.1 | -5.2 | -6.5 | -9.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.5 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 7.5% | 0.0% |
| Earnings from continuing ops | -7.4 | -7.9 | -6.3 | -7.1 | -5.1 | -5.2 | -6.5 | -9.2 |
| Earnings from discontinued ops | | | | | | 0.2 | 0.5 | 0.0 |
| Net income | -7.4 | -7.9 | -6.3 | -7.1 | -5.1 | -5.0 | -6.0 | -10.6 |
| Net margin | -295.0% | -548.1% | -350.0% | -290.5% | -228.9% | -175.9% | -299.7% | -978.5% |
| |
| Diluted EPS | ($0.04) | ($0.05) | ($0.05) | ($0.08) | ($0.14) | ($0.14) | ($0.18) | ($0.29) |
| Shares outstanding (diluted) | 197.1 | 172.8 | 123.8 | 90.4 | 36.8 | 36.7 | 35.7 | 32.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|